MGCD0103

Background Information:

MGCD0103 is a rationally designed, oral, isotype-selective, small
molecule HDAC inhibitor, selectively targeting HDACs 1, 2, 3 and 11 with
IC50s at low micromolars. MGCD0103 displays promising antitumor
activity in hematological and lymphoproliferative diseases, currently in
clinical trials.

Reference:

1. Reisman, David. Polymorphisms in BRM gene associated with cancer
cells and methods for diagnosis and drug screening for antitumor agents.
U.S. Pat. Appl. Publ. (2010), 59pp., Cont.-in-part of U.S. Ser. No.
365,268. CODEN: USXXCO US 2010087328 A1 20100408 CAN 152:446756 AN
2010:442057.
2. Bradner, James E.; West, Nathan; Grachan, Melissa L.; Greenberg,
Edward F.; Haggarty, Stephen J.; Warnow, Tandy; Mazitschek, Ralph.
Chemical phylogenetics of histone deacetylases. Nature Chemical Biology
(2010), 6(3), 238-243.
3. Reisman, David. BRM expression in cancer cells and related
diagnostics and treatment. PCT Int. Appl. (2010), 87pp. CODEN: PIXXD2 WO
2010014582 A2 20100204 CAN 152:231205 AN 2010:146930.

APIM050338: MGCD0103

CAS No.: 726169-73-9.
Molecular Formula: C₂₃H₂₀N₆O.
Molecular Weight: 396.4.
Purity: >99.5% (by HPLC).
QC: HPLC, ¹HNMR, and Quantitative Elemental Analysis.
Solubility: Soluble in DMSO.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.